Heartflow, INC Form 4 insider transactions

Heartflow, Inc. CEO John Farquhar reported a transaction involving the sale of common stock, executed under a pre-arranged 10b5-1 trading plan.

Heartflow, Inc. Chief Medical Officer Campbell Rogers reports significant transactions involving common stock, including option exercises and sales, executed under a Rule 10b5-1 trading plan.

Heartflow Director Jeffrey C. Lightcap reported a pro rata in-kind distribution of 206,261 common shares, transitioning ownership from indirect to direct.

HealthCor Partners Management LP, a director and 10% owner of Heartflow, Inc., reported a planned distribution of over 4.6 million common shares to fund investors.

Heartflow's Chief Medical Officer, Campbell Rogers, exercised stock options and subsequently sold a portion of his common stock holdings, all under a pre-arranged 10b5-1 trading plan.

Heartflow, Inc. CEO John C.M. Farquhar sold 9,725 shares of common stock for $25 per share under a pre-arranged trading plan.

Heartflow, Inc. Director Timothy C. Barabe exercised 8,667 stock options, acquiring common stock at $2.22 per share.

Heartflow CEO John C.M. Farquhar reported the sale of 12,837 common shares under a Rule 10b5-1 trading plan, following an acquisition of 2,631 shares via an Employee Stock Purchase Plan.

Heartflow Director Julie A Cullivan sold 9,122 shares of common stock for $25 per share, reducing her direct beneficial ownership to 27,291 shares.

Heartflow Director Timothy C. Barabe exercised stock options to acquire 2,497 shares of common stock at $8.33 per share under a pre-planned trading arrangement.

Heartflow's Chief Accounting Officer, Marie L. Jones, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.

Heartflow CEO John C.M. Farquhar reported recent transactions including RSU grants, option awards, and a sale of common stock.

Heartflow's Chief Medical Officer, Campbell Rogers, reported new equity awards including restricted stock units and stock options, alongside a tax-related share disposal.

Heartflow's Chief Financial Officer, Vikram Verghese, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.

Heartflow Director Julie A. Cullivan sold 8,000 shares of common stock at $27.32 per share pursuant to a pre-arranged Rule 10b5-1 trading plan.

Bain Capital Life Sciences Investors and related entities reported the sale of 2 million shares of Heartflow, Inc. common stock at $28.05 per share, reducing their indirect beneficial ownership to 10,448,158 shares.

Heartflow Director Jeffrey C Lightcap purchased 40,000 shares of common stock at a weighted average price of $26.342, signaling increased insider confidence.

Heartflow's Chief Medical Officer, Campbell Rogers, disposed of 439 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Heartflow, Inc. CEO John C.M. Farquhar reported a disposition of 1,339 common shares to cover tax obligations related to restricted stock unit vesting.

Heartflow's Chief Financial Officer, Vikram Verghese, disposed of 471 shares of common stock to cover tax obligations related to vested restricted stock units.

Heartflow's Chief Accounting Officer, Marie L. Jones, disposed of 81 common shares to cover tax withholding obligations related to restricted stock unit vesting.

HealthCor Partners entities plan to convert significant preferred stock and convertible notes into Heartflow common stock by August 2025.

Bain Capital Life Sciences entities converted Series F Preferred Stock and a Subordinated Convertible Promissory Note into Heartflow, Inc. common stock.

Heartflow, Inc. Director Julie A. Cullivan was granted 23,710 stock options with an exercise price of $19, vesting over one year.

Heartflow Director William C. Weldon acquired 136,286 common shares through preferred stock conversions and was granted 23,710 stock options.

Heartflow, Inc. Director Wayne Joseph Riley was granted 23,710 stock options with an exercise price of $19, set to vest by August 2026.

Heartflow, Inc. CEO John C.M. Farquhar received grants of 59,868 restricted stock units and options for 314,603 shares of common stock.

Heartflow's Chief Financial Officer, Vikram Verghese, reported the acquisition of restricted stock units and stock options, alongside the conversion of a promissory note into common stock.

Heartflow's Chief Medical Officer, Campbell Rogers, was granted 21,052 Restricted Stock Units and 110,629 stock options, vesting over several years.

Heartflow's Chief Accounting Officer, Marie L. Jones, reported the acquisition of restricted stock units, stock options, and the conversion of promissory notes into common stock.